ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/BRAF
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/BRAF
13
trial(s) found.
NCT06346067
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2] (
ERAS-254-02
)
MEK inhibitor
RAF dimer inhibitor
alkylating agent
+ BRAF inhibitor
Melanoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Hollywood Private Hospital
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
+ BRAF inhibitor
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
+ BRAF inhibitor
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05907304
Advanced
Phase 1
Recruiting
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations (
SEACRAFT-1
)
MEK inhibitor
RAF dimer inhibitor
+ BRAF inhibitor
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Linear Clinical Research
NCT05828069
Haem
Phase 2
Recruiting
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis (
NCI-2022-06282
)
RAF inhibitor,type 2
+ BRAF inhibitor
Langerhans Cell Histiocytosis
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05503797
Advanced
Phase 2
Recruiting
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations (
F8394-201
)
RAF dimer inhibitor
+ BRAF inhibitor
Cancer
Central nervous system cancer
Melanoma
NOT Colorectal adenocarcinoma
NOT Melanoma
NOT Non-small cell lung cancer
NOT Pancreatic adenocarcinoma
NOT Thyroid cancer
Solid tumour
Thyroid cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05203172
Advanced
Phase 4
Recruiting
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES (
C4221026
)
BRAF V600 inhibitor
MEK inhibitor
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05182931
Advanced
Phase 2
Recruiting
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (
I-FIRST
Study)
BRAF V600 inhibitor
BRAF inhibitor
Dabrafenib
MEK inhibitor
RAF inhibitor
Trametinib
cancer therapy
cancer therapy,BRAF-targeting
cancer therapy,BRAF V600-targeting
cancer therapy,MEK-targeting
cancer therapy,RAF-targeting
+ BRAF V600 inhibitor
NOT Anaplastic thyroid cancer
Thyroid cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3181 - Prahran - The Alfred Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06194877
Advanced
Phase 1
Terminated
A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 With Panitumumab in Patients With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (
BGB-3245-EGFR-001
)
RAF dimer inhibitor
anti-EGFR monoclonal antibody
+ BRAF inhibitor
Colorectal adenocarcinoma
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05743036
Advanced
Phase 1
Active not recruiting
A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer (
ZN-c3-016
)
BRAF V600 inhibitor
WEE1 inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05580770
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors (
MEKRAF-AST-101
)
MEK inhibitor
RAF dimer inhibitor
+ BRAF inhibitor
Melanoma
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05270044
Curative
Phase 3
Active not recruiting
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group (
COLUMBUS-AD
)
BRAF V600 inhibitor
MEK inhibitor
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Hollywood Private Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05217446
Advanced
Phase 2
Active not recruiting
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER (
SEAMARK
)
BRAF V600 inhibitor
anti-EGFR monoclonal antibody
anti-PD-1 monoclonal antibody
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (8)
Active not recruiting (3)
Terminated (2)
Recruitment Country and State
VIC (12)
NSW (10)
QLD (6)
WA (5)
SA (5)
NZ (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (1)
Phase 2 (4)
Phase 3 (3)
Phase 4 (1)
Trial Type
Advanced (11)
Haem (1)
Curative (1)
Cancer Therapy Class
BRAF
100%
RAF
100%
MEK
62%
BRAF V600
38%
EGFR
31%
CRAF
23%
pan-RAF
23%
FAK
8%
oestrogen axis
8%
CDK4
8%
CDK6
8%
WEE1
8%
PD-1
8%
PD-1/PD-L1
8%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3004 - Melbourne, Southbank - Alfred Health (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
6009 - Nedlands - Hollywood Private Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2031 - Randwick - Sydney Children's Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3181 - Prahran - The Alfred Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4215 - Southport - Tasman Oncology (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2031 - Randwick - Prince of Wales Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2109 - North Ryde - Macquarie University Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
6009 - Nedlands - Linear Clinical Research (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
Cancer Type
Cancer
Solid tumour
Melanoma
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Central nervous system cancer
Lung cancer
Neurological cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Endocrine gland cancer
Thyroid cancer
Glioma
Epithelial Ovarian Cancer
Gynaecological cancer
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Haematological malignancy
Histiocytic and dendritic cell neoplasm
Histiocytic neoplasm
Langerhans Cell Histiocytosis
Colorectal adenocarcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy